Tumours can arise from thyroid follicular cells if they acquire driver mutations that
constitutively activate the MAPK signalling pathway. In addition, a limited set of additional …

TERT promoter mutations (TERT-p mutations) have been found in many types of cancer and
have emerged to play critical roles in tumor progression. The mutations upregulate TERT …

Purpose: The determinants of response or resistance to radioiodine (RAI) are unknown. We
aimed to identify genomic and transcriptomic factors associated with structural responses to …

Context Patients with differentiated thyroid cancer (DTC) with distant metastasis (DM) are
usually not recognized as radioactive iodine (RAI)-refractory DTC in a timely manner. The …

The introduction and generalization of next-generation sequencing techniques have
significantly increased the identification of mutations in thyroid tumors from multiple patient …

Simple Summary [18F] FDG-PET/CT is a new imaging modality used in routine practice for
many tumor diseases. The combination of morphological and metabolic information has …

Context Lenvatinib is approved for the treatment of radioiodine-refractory differentiated
thyroid cancer (RR-DTC). The definition of predictive factors of survival is incomplete …

Thyroid cancers are often initiated by the acquisition of a BRAF V600E mutation. BRAF
V600E-driven thyroid tumors display a wide range of behaviors, from the slow-growing …

Objective Patients with radioactive iodine-refractory differentiated thyroid cancer (RAIR-
DTC) are often diagnosed with delay and constrained to limited treatment options. The …

Effects of the tumor microenvironment (TME) stromal cells on progression in thyroid cancer
are largely unexplored. Elucidating the effects and underlying mechanisms may facilitate the …